DHHC5 regulates intestinal lipid absorption and lymphatic function
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Jun-2025 23:10 ET (29-Jun-2025 03:10 GMT/UTC)
Esophageal cancer is a prevalent and aggressive malignancy associated with a poor prognosis. Metabolomics and microbiomics have emerged as promising approaches for investigating the tumor microenvironment and monitoring dynamic changes throughout the treatment process. These methodologies facilitate the direct observation of phenotypic alterations with high sensitivity, throughput, and adaptability across diverse sample types. Microbial genomic data play a crucial role in predicting the metabolic potential of microorganisms, whereas metabolomics offers direct evidence of active metabolic pathways under specific conditions. This review presents novel insights into the pathogenesis, diagnosis, and treatment of esophageal cancer through the application of metabolomics and microbiomics. Future advancements in the integration of multi-omics data are expected to further elucidate the metabolic mechanisms and pathophysiological processes underlying esophageal cancer, thereby laying a robust scientific foundation for early diagnosis, prognostic assessment, and personalized treatment strategies.
A research team reveals the promising antihypertensive effects of egg white hydrolysates (EWH) and ovotransferrin-depleted egg white hydrolysates (OD-EWH) in spontaneously hypertensive rats (SHRs), suggesting that these natural ingredients could be effective alternatives to traditional pharmaceuticals for managing hypertension.
A collaborative team from the University of Macau and Nanjing University found, using clinical databases and samples, that the loss of a protein named MFG-E8 in nucleus pulposus (NP) tissue is a factor in intervertebral disc degeneration (IDD), the leading cause of back pain worldwide. They suspected that MFG-E8 is bound to the glycan matrix in the NP tissue, but increasing the enzymes during IDD cleaves the glycans, releasing MFG-E8 and affecting the cell phenotype. Accordingly, they devised a glycan molecule, called GMOC, that is similar to the native glycan matrix but escapes the cleavage from enzymes that cleave the native glycans. They injected GMOC into rat and rabbit models of IDD and observed amelioration of symptoms, providing new insights for developing therapeutic strategies for future IDD treatment. The study was recently published in Nature Communications (https://rdcu.be/ejPlG).